Answer

Caution is strongly advised when taking green tea with GI prokinetics (specifically cisapride). This combination may increase the plasma concentration of the medication, raising the risk of toxicity and severe adverse effects.

Evidence Assessment

Evidence Strength: Preliminary/Weak (Tier D) The assessment is based on pharmacological inference via the Flockhart CYP450 Table rather than randomized controlled trials or clinical case reports. While the biochemical mechanism is plausible, the clinical significance in a general population has not been quantified in a dedicated study.

Clinical Evidence

The interaction is driven by the metabolic pathway of cisapride, a prokinetic agent that is primarily metabolized by the cytochrome P450 enzyme CYP3A4. Green tea contains compounds that act as weak inhibitors of CYP3A4.

When a CYP3A4 inhibitor is introduced, the metabolism of the substrate (cisapride) is slowed, leading to increased systemic exposure and higher plasma levels. Because cisapride has a narrow therapeutic index and is associated with serious cardiac risks—specifically QT interval prolongation which can lead to Torsades de Pointes—any increase in plasma concentration significantly elevates the risk of life-threatening arrhythmias.

Practical Guidance

If a patient is currently prescribed a GI prokinetic like cisapride, the following is recommended: * Avoid High-Dose Extracts: While a casual cup of brewed green tea may have a negligible effect, concentrated green tea extracts (EGCG) provide a higher dose of inhibitors and pose a greater risk. * Monitoring: Patients should be monitored for signs of cisapride toxicity, including severe diarrhea, abdominal cramping, or cardiac symptoms (palpitations, dizziness). * Alternative: Consider alternative non-CYP3A4 inhibiting supplements for antioxidant support if a prokinetic is necessary.

Safety & Interactions

Contraindication: Caution / Monitor Closely

• Drug Class & Mechanism: CYP3A4 Inhibitor (Green Tea) $\rightarrow$ CYP3A4 Substrate (Cisapride). The inhibition of the enzyme decreases the clearance of the drug.
• Clinical Management: If combined, a dose reduction of the prokinetic may be necessary under medical supervision. Patients should be screened for baseline cardiac health.
• High-Risk Populations:
  • Cardiac Patients: Those with pre-existing long QT syndrome or heart failure are at extreme risk.
  • Elderly: Reduced hepatic clearance in older adults may exacerbate the interaction.
  • Polypharmacy: Patients taking other CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) must avoid green tea extracts entirely.

Consult a healthcare provider before combining these substances.